

PEDIATRIX MEDICAL GROUP, INC.
RECONCILIATION OF (LOSS) INCOME FROM CONTINUING OPERATIONS
TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO PEDIATRIX MEDICAL GROUP, INC.
(in thousands)
(Unaudited)

	Three Months Ended March 31, 2022	Three Months Ended June 30, 2022	Three Months Ended September 30, 2022	Three Months Ended December 31, 2022	Twelve Months Ended December 31, 2022
(Loss) income from continuing operations attributable to Pediatrix Medical Group, Inc.	\$ (20,941)	\$ 30,701	\$ 28,808	\$ 24,000	\$ 62,568
Interest expense	11,818	8,409	9,516	9,952	39,695
Loss on early extinguishment of debt	57,016	-	-	-	57,016
Income tax (benefit) provision	(7,401)	12,332	10,051	3,824	18,806
Depreciation and amortization expense	8,769	8,775	8,956	9,136	35,636
Transformational and restructuring related expenses	1,421	5,338	977	19,576	27,312
Adjusted EBITDA from continuing operations attributable to Pediatrix Medical Group, Inc	<u>\$ 50,682</u>	<u>\$ 65,555</u>	<u>\$ 58,308</u>	<u>\$ 66,488</u>	<u>\$ 241,033</u>